Evidence map›Paper›PMID 39131016›Full record

ReviewCureus2024

Emerging Therapeutic Strategies in Cardiovascular Diseases.

Rajinderpal Singh, Sohbat Kaur Chandi, Seerat Sran, Smriti K Aulakh, Gurkamal Singh Nijjar, Kanwarmandeep Singh, Sumerjit Singh, Fnu Tanvir, Yasmeen Kaur, Ajay Pal Singh Sandhu

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Phenotypic Switching of VSMCs in the Development of CVDs: Focus on miRs.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rajinderpal SinghInternal Medicine, Government Medical College Amritsar, Amritsar, IND.
Sohbat Kaur ChandiInternal Medicine, Government Medical College Amritsar, Amritsar, IND.
Seerat SranInternal Medicine, Sri Guru Ram Das University of Health Sciences and Research, Amritsar, IND.
Smriti K AulakhInternal Medicine, Sri Guru Ram Das University of Health Sciences and Research, Amritsar, IND.
Gurkamal Singh NijjarMedicine, Government Medical College Amritsar, Amritsar, IND.
Kanwarmandeep SinghMedicine, Government Medical College Amritsar, Amritsar, IND.
Sumerjit SinghMedicine, Government Medical College Amritsar, Amritsar, IND.
Fnu TanvirMedicine, Government Medical College Amritsar, Amritsar, IND.
Yasmeen KaurMedicine, Government Medical College Amritsar, Amritsar, IND.
Ajay Pal Singh SandhuMedicine, Sri Guru Ram Das University of Health Sciences and Research, Amritsar, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs), including ischemic heart disease and stroke, are the leading cause of mortality worldwide, causing nearly 20 million deaths annually. Traditional therapies, while effective, have not curbed the rising prevalence of CVDs driven by aging populations and lifestyle factors. This review highlights innovative therapeutic strategies that show promise in improving patient outcomes and transforming cardiovascular care. Emerging pharmacological treatments, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors, introduce novel mechanisms to complement existing therapies, significantly reducing cardiovascular events and mortality. These advancements emphasize the necessity of ongoing clinical trials and research to discover new therapeutic targets. Advanced biological therapies, including gene therapy, stem cell therapy, and RNA-based treatments, offer groundbreaking potential for repairing and regenerating damaged cardiovascular tissues. Despite being in various stages of clinical validation, early results are promising, suggesting these therapies could fundamentally change the CVD treatment landscape. Innovative medical devices and technologies, such as implantable devices, minimally invasive procedures, and wearable technology, are revolutionizing CVD management. These advancements facilitate early diagnosis, continuous monitoring, and effective treatment, driving care out of hospitals and into homes, improving patient outcomes and reducing healthcare costs. Personalized medicine, driven by genetic profiling and biomarker identification, allows for tailored therapies that enhance treatment efficacy and minimize adverse effects. However, the adoption of these emerging therapies faces significant challenges, including regulatory hurdles, cost and accessibility issues, and ethical considerations. Addressing these barriers and fostering interdisciplinary collaboration are crucial for accelerating the development and implementation of innovative treatments. Integrating emerging therapeutic strategies in cardiovascular care holds immense potential to transform CVD management. By prioritizing future research and overcoming existing challenges, a new era of personalized, effective, and accessible cardiovascular care can be achieved.

Indexed as

cardiovascular diseasesemerging therapiesemerging treatmentsgene therapyischemic heart diseasepharmacological treatmentsrna-based therapiesstem cell therapystroketherapeutic strategies

Identifiers

PMID39131016
PMCPMC11317025

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.